Keep Calm and Treat to Target in Inflammatory Bowel Disease

  • Home / Keep Calm and Treat to Target in Inflammatory Bowel Disease

Keep Calm and Treat to Target in Inflammatory Bowel Disease

This symposium took place on 30th October 2017, as part of the 25th United European Gastroenterology (UEG) Week in Barcelona, Spain

Chairperson: Jean-Frédéric Colombel1
Speakers: Jean-Frédéric Colombel,1 Benjamin Pariente,2 Geert D’Haens3

1. Icahn School of Medicine at Mount Sinai, New York City, New York, USA
2. Gastroenterology Department, Claude Huriez Hospital, University of Lille, Lille, France
3. Academic Medical Centre, Amsterdam, Netherlands

Disclosure: Prof Colombel has acted as a consultant or advisory board member for AbbVie, ABScience, Amgen, Bristol-Myers Squibb, Celltrion, Danone, Ferring, Genentech, Giuliani SPA, Given Imaging, Janssen, Immune Pharmaceuticals, Medimmune, Merck & Co, Millenium Pharmaceuticals Inc, Neovacs, Nutrition Science Partners Ltd, Pfizer Inc, Prometheus Laboratories, Protagonist, Receptos, Sanofi, Schering Plough Corporation, Second Genome, Shire, Takeda, Teva Pharmaceuticals, Tigenix, UCB Pharma, Vertex, and Dr August Wolff GmbH & Co.; and a speaker for AbbVie, Falk, Ferring, Janssen, Merck & Co, Nutrition Science Partners Ltd, Takeda. Dr Pariente has received consulting fees from AbbVie, MSD, Ferring, Takeda, Janssen, Bioagaran, and Pfizer. Prof D’Haens has acted as an advisor for AbbVie, Ablynx, Amakem, Amgen, AM-Pharma, Avaxia, Biogen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene/Receptos, Celltrion, Cosmo, Covidien/Medtronic, Ferring, DrFALK Pharma, Eli Lilly, Engene, Galapagos, Genentech/Roche, Gilead, GlaxoSmithKline, Immunic, Johnson & Johnson, Lycera, Medimetrics, Millenium/Takeda, Mitsubishi Pharma, Merck Sharp Dohme, Mundipharma, Nextbiotics, Novo Nordisk, Otsuka, Pfizer/Hospira, Prometheus laboratories/Nestlé, Protagonist, Robarts Clinical Trials, Salix, Samsung Bioepis, Sandoz, SetPoint, Shire, Teva, TiGenix, Tillotts, Topivert, Versant, and Vifor; and has received speaker fees from AbbVie, Biogen, Ferring, Johnson & Johnson, Merck Sharp Dohme, Mundipharma, Norgine, Pfizer, Samsung Bioepis, Shire, Millenium/Takeda, Tillotts, and Vifor.
Acknowledgements: Writing assistance was provided by Janet Fricker.
Support: The symposium and the publication of this article was funded by AbbVie. The views and opinions expressed are those of the authors and not necessarily of AbbVie.
Citation: EMJ Gastroenterol. 2017;6[1]:32-39.

Meeting Summary

The goal of this symposium was to highlight the importance of early diagnosis, assessing prognostic factors, and treating to target in inflammatory bowel disease (IBD). In the introduction, Prof Colombel outlined the treat to target (T2T) and tight control (TC) approach, which involves predefining treatment targets in consultation with patients, continuously monitoring disease activity, and modifying treatments until targets are achieved. Dr Pariente presented regarding the progressiveness of Crohn’s disease (CD) and described the Lémann index (LI), which assesses cumulative structural damage in CD.1 He outlined the ‘window of opportunity’ in early disease, within which disease progression could be stopped. Dr Pariente said the T2T approach presents the opportunity for a personalised method of treatment; if targets are not achieved, treatment is intensified or switched. Prof Colombel presented the results of the CALM study,2 in which CD patients were randomised 1:1 to clinical management (CM) or TC, meaning treatment was escalated based on clinical symptoms in combination with biomarkers. The primary endpoint of mucosal healing and no deep ulceration was achieved by 45.9% of patients in the TC arm versus 30.3% in the CM arm (p=0.010). Lastly, Prof D’Haens presented a cost-effectiveness analysis using data from CALM. The calculated total direct medical costs for the TC arm were £13,296 versus £12,627 for the CM arm (a direct medical cost difference of £669).3 The quality-adjusted life years (QALY) were 0.684 for the TC arm versus 0.652 for the CM arm (giving a QALY difference of 0.032). The incremental cost-effectiveness ratio showed a cost of £20,913 per QALY gained, which falls within the threshold of The National Institute for Health and Care Excellence (NICE) guidance for cost-effectiveness.

This article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

The post Keep Calm and Treat to Target in Inflammatory Bowel Disease appeared first on European Medical Journal.

About Post Author

Medical CPD & News

The Digitalis CPD trawler searches the web for all the latest news and journals.

Privacy Preference Center

Close your account?

Your account will be closed and all data will be permanently deleted and cannot be recovered. Are you sure?

Are you sure?

By disagreeing you will no longer have access to our site and will be logged out.